News and Publications

Respiree Pte Ltd made it through the first round and has been selected as a Finalist for Falling Walls Venture 2022

Digital health startup Respiree has raised S$4.7 million in Series Seed equity funding led by Oriza Greenwillow Technology Fund, SEEDS capital and high-net-worth investors that include the she1K angel syndicate. 

Amidst this pandemic, Singapore continues to invest in science and innovation, as well as grow a strong pool of talented scientists – some of whom contribute to the fight against Covid-19 using AI analytics. 

Dedicated to research and innovation for the public good, the Agency for Science, Technology and Research (A*STAR) interviews 2 of their scholars; Dr Sarah Luo, Principal Investigator at the Institute of Molecular and Cell Biology (IMCB), and Dr Gurpreet Singh, Senior Research Scientist at the Institute of Bioengineering and Bioimaging (IBB) and founder of Respiree Pte Ltd.

For Professor Patrick Cozzone, Executive Director of the Singapore Bioimaging Consortium and cofounder of Respiree, bioimaging lies at the heart of understanding fundamental biological processes.

Local medical technology startup Respiree’s wearable device which is used to measure vital parameters such as respiratory rate or blood oxygen levels.

Digital tools that free up time and resources for clinical staff are a breath of fresh air in these pressing times – particularly when they can generate invaluable patient data. Roche Diagram magazine explores what these innovations mean for practitioners.

Founded in 2019, Respiree’s technology is based on core sensor technology developed at the Singapore Bioimaging Consortium (SBIC), at A*STAR. Gurpreet Singh, Founder of Respiree and A*STAR scholar, shares how he turned a discovery in the lab into a device that could potentially save lives.

Local medical technology start-up Respiree aims to deploy respiratory bio-markers to predict worsening conditions in Covid-19 patients in isolation rooms.

Early identification and therapeutic intervention are key to reducing risk for individuals at risk of acute respiratory failure and pneumonia from COVID-19 – such is the core of the collaboration between the National University Hospital (NUH), NUS Yong Loo Lin School of Medicine (NUS Medicine) and Respiree Pte Ltd.